Subscribe to RSS
DOI: 10.1055/a-2408-3429
Amendment “New nomenclature for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)” to the S2k guideline “Non-alcoholic fatty liver disease” (v.2.0/April 2022) of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)
March 2024 – AWMF Register Number: 021-025
Table of contents |
Page |
|
List of abbreviations |
2066 |
|
List of tables |
2066 |
|
List of figures |
2066 |
|
1 |
Information on the amendment |
2066 |
1.1 |
Publisher |
2066 |
1.2 |
Leading professional association |
2066 |
1.3 |
Scope and purpose |
2066 |
1.4 |
Goal orientation of the amendment |
2067 |
1.5 |
Service area |
2067 |
1.6 |
User target group/addressees |
2067 |
1.7 |
Composition of the guideline group: participation of interest groups |
2067 |
1.8 |
Representativeness of the guideline group: participating professional associations/institutions |
2067 |
1.9 |
Representativeness of the guideline group: participation of patient representatives |
2068 |
2 |
Methodological approach |
2068 |
2.1 |
Schedule |
2069 |
3 |
External review and approval |
2069 |
3.1 |
Adoption by the boards of the publishing professional societies/organizations |
2069 |
3.2 |
Editorial independence and financing of the guideline |
2069 |
3.3 |
Disclosure of and dealing with conflicts of interest |
2069 |
4 |
Dissemination and implementation |
2069 |
4.1 |
Concept for dissemination and implementation |
2069 |
4.2 |
Validity period and updating procedure |
2069 |
5 |
Editorial note |
2069 |
5.1 |
Gender-neutral wording |
2069 |
5.2 |
Participatory decision-making |
2069 |
5.3 |
Special note |
2070 |
1 Amendment – New nomenclature for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) [consensus] |
2070 |
|
References |
2074 |
List of abbreviations
Publication History
Article published online:
06 December 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542-1556
- 2 Ludwig J, Viggiano TR, McGill DB. et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438
- 3 Geier A, Tiniakos D, Denk H. et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021; 70: 1570-1579
- 4 Roeb E, Canbay A, Bantel H. et al. Updated S2k guideline non-alcoholic fatty liver disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF registry number: 021-025. Z Gastroenterol 2022; 60: 1346-1421
- 5 Roeb E, Steffen HM, Bantel H. et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 2015; 53: 668-723
- 6 Eslam M, Newsome PN, Sarin SK. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73: 202-209
- 7 Loomba R, Ratziu V, Harrison SA. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology 2022; 162: 680-688
- 8 Israelsen M, Torp N, Johansen S. et al. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol 2023; 8: 866-868
- 9 Åberg F, Byrne CD, Pirola CJ. et al. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol 2023; 78: 191-206
- 10 Ciardullo S, Carbone M, Invernizzi P. et al. Exploring the landscape of steatotic liver disease in the general US population. Liver Int 2023; 43: 2425-2433
- 11 Mózes FE, Lee JA, Vali Y. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 704-713
- 12 Vali Y, Lee J, Boursier J. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol 2023; 8: 714-725
- 13 Hardy T, Wonders K, Younes R. et al. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020; 98: 106175
- 14 Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and sub-classifications using consensus nomenclature. Hepatology 2023;
- 15 Hagström H, Vessby J, Ekstedt M. et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 2023;
- 16 Siddiqui MS, Harrison SA, Abdelmalek MF. et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018; 67: 2001-2012
- 17 Younossi ZM, Stepanova M, Taub RA. et al. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2022; 20: 1354-1361
- 18 Harrison SA, Taub R, Neff GW. et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2023; 29: 2919-2928
- 19 Li M, Zhang W, Li X. et al. Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults. Nutrients 2023; 15
- 20 Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther 2017; 46: 85-95